Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (Weighted Average) (2016 - 2025)

Ocular Therapeutix (OCUL) has 11 years of Shares Outstanding (Weighted Average) data on record, last reported at $183.9 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 10.14% year-over-year to $183.9 million; the TTM value through Sep 2025 reached $183.9 million, up 10.14%, while the annual FY2020 figure was $60.8 million, 34.19% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $183.9 million in Q3 2025 per OCUL's latest filing, up from $171.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $183.9 million in Q3 2025 and bottomed at $77.4 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $143.1 million, with a median of $166.4 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 112.47% in 2024, then grew 3.12% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $78.0 million in 2023, then skyrocketed by 113.96% to $167.0 million in 2024, then rose by 10.14% to $183.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $183.9 million in Q3 2025, $171.0 million in Q2 2025, and $169.4 million in Q1 2025.